| 000 | 01708 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518072934.0 | ||
| 264 | 0 | _c20200309 | |
| 008 | 202003s 0 0 eng d | ||
| 022 | _a1423-0232 | ||
| 024 | 7 |
_a10.1159/000504578 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKarachaliou, Georgia Sofia | |
| 245 | 0 | 0 |
_aChemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III/Stage IV Metastatic Melanoma: A Single Academic Institution Experience. _h[electronic resource] |
| 260 |
_bOncology _c2020 |
||
| 300 |
_a174-178 p. _bdigital |
||
| 500 | _aPublication Type: News | ||
| 650 | 0 | 4 | _aAcademic Medical Centers |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xadverse effects |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aNorth Carolina |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
| 650 | 0 | 4 | _aProgression-Free Survival |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSkin Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aTemozolomide _xadverse effects |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aAyvali, Fatih | |
| 700 | 1 | _aCollichio, Frances A | |
| 700 | 1 | _aLee, Carrie B | |
| 700 | 1 | _aIvanova, Anastasia | |
| 700 | 1 | _aOllila, David W | |
| 700 | 1 | _aMoschos, Stergios J | |
| 773 | 0 |
_tOncology _gvol. 98 _gno. 3 _gp. 174-178 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1159/000504578 _zAvailable from publisher's website |
| 999 |
_c30379249 _d30379249 |
||